drugset
drugset / Trial / NCT06908694

Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

NCT06908694 ↗

Phase 4 Recruiting 20 enrolled Hamilton Health Sciences Corporation McMaster University · collab
NaSingle-groupOpen-labelTreatment

Summary

GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.

Timeline

Start
2025-07-02
Primary completion
2026-07-31
Completion
2026-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 2.4 mg Subcutaneous

Indications

prostate cancer